Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra

Salunke, Aarti S.; Nagargoje, Mahendra Vinayak; Belgaumkar, Vasudha Abhijit; Tolat, Sunil N.; Chavan, Ravindranath Brahmadev

doi:10.7860/jcdr/2017/24390.10348

Cited by 20 publications

(35 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obesity is a risk factor for cardiovascular and other diseases, and is also a common comorbidity of psoriasis, with reports of prevalence ranging from 15.2% (in a study of the Czech national registry of psoriatic patients treated with biologics, and a comparison with other European registries) 8 to 32.6% (a study of prevalence of metabolic disease and its various components comparing 95 psoriatic patients to 95 controls). 16 A French study of 2,210 patients reports the prevalence to be 24%, 12 while a large study over 48,000, and another of over 15,000 patients, report 20.36% 5 and 24.3% 7 respectively. Trattner et al report 27% in a study of plantar pustulosis.…”

Section: Obesitymentioning

confidence: 98%

See 1 more Smart Citation

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Vebman¹,

Choy²,

Yao³

2020

J of Skin

View full text Add to dashboard Cite

Introduction:-Psoriasis is a common disease that is linked with several other diseases. Our goals were to analyze and present literature on prevalence of various psoriatic comorbidities, and provide an estimate of what percent of psoriasis patients might have or develop Myocardial/cardiovascular/heart disease, stroke, diabetes, obesity, hypertension, or metabolic syndrome.Method:-To collect the results, we searched PubMed to identify papers that studied the frequency of the most common comorbidities of psoriasis. We used about 20. The search terms used were the particular comorbidity (or synonyms) and psoriasis. Papers were selected where the prevalence data were listed by percentages of the studied population. Prevalence data from each paper were collected and charted, and then compared. We did not use data that concerned Psoriatic Arthritis. We also recorded outliers, where frequencies did not fit with the other data found.Results:-Results for prevalence of myocardial/cardiovascular/heart disease were mixed, varying by age and severity of disease. There are few papers on prevalence of stroke, but our review suggests risk of stroke increases with severity of psoriasis. The prevalence of diabetes was largely between 10% and 20%. Obesity’s prevalence was mostly between 15% and 30%, while hypertension hovered around 30%, and metabolic syndrome prevalence was mostly between 27% and 50%.Conclusions:-There are many comorbidities of psoriasis. The complex interaction between cutaneous inflammation and heart disease, stroke, diabetes, hypertension and metabolic syndrome raises many questions about cause and effect or simple association.

show abstract

Section: Obesitymentioning

confidence: 98%

“…Salunke et al reports a prevalence rate of hypertension at 18.9%, but found that the rates increased with the duration of psoriasis. 16 The Malaysian study reports prevalence rate of 25.6%. 7 Many studies show results in a consistent range.…”

Section: Hypertensionmentioning

confidence: 99%

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Vebman¹,

Choy²,

Yao³

2020

J of Skin

View full text Add to dashboard Cite

show abstract

“…Recently, numerous studies have shown a positive association between metabolic syndrome and adult psoriasis . However, limited studies have been done on the association between metabolic syndrome and pediatric psoriasis.…”

Section: Introductionmentioning

confidence: 99%

“…1 Recently, numerous studies have shown a positive association between metabolic syndrome and adult psoriasis. [3][4][5][6][7][8] However, limited studies have been done on the association between metabolic syndrome and pediatric psoriasis. A metaanalysis of seven studies, which assessed the metabolic syndrome and cardiovascular risks of pediatric psoriasis, found that children with psoriasis had 6.10 times the risk of having metabolic syndrome than children without psoriasis (in only three studies).…”

Section: Introductionmentioning

confidence: 99%

Association of metabolic syndrome with pediatric psoriasis: a case‐control study in Kabul, Afghanistan

2020

View full text Add to dashboard Cite

Background Limited studies have assessed the risk of metabolic syndrome in pediatric psoriasis. This study was aimed to investigate the association of obesity and metabolic syndrome with pediatric psoriasis in Afghanistan. Methods A case‐control study was conducted from March to December 2018 at the dermatology department of Maiwand Teaching Hospital in Kabul city. Participants were children aged less than 18 years; 113 children with psoriasis and 113 children without psoriasis were compared. Height, weight, waist circumference, and blood pressure were measured. Blood samples were taken following overnight fasting to test serum levels of glucose, triglyceride, cholesterol, and high‐density lipoprotein cholesterol. Analyses were done using Chi‐square test and independent t test. Odds ratio and 95% confidence interval were calculated. Results The mean age was 13.9 ± 3.7 and 13.4 ± 3.4 years in the psoriasis and control groups, respectively. Males comprised 54.9% of the psoriasis group and 41.6% of the control group. Family history of skin disorders was higher among children with psoriasis compared to the control group (23.0% vs. 13.7%; P < 0.001). Children with psoriasis were more likely to be overweight/obese (27.4% vs. 12.4%, OR = 2.67; P = 0.005), to have central adiposity with waist‐height ratio of 0.5 or greater (23% vs. 9.7%, OR = 2.77; P = 0.007), and to have metabolic syndrome (13.3% vs. 2.3%, OR = 5.23; P = 0.005). Conclusion The study revealed that children with psoriasis were more likely to have metabolic syndrome and cardiovascular risk factors compared to children without psoriasis.

show abstract

“…В настоящее время к состояниям, коморбидным псориазу, принято относить артериальную гипертен-зию, сахарный диабет II типа, гиперлипидемию, ожирение, метаболический синдром, ишемическую болезнь сердца, атеросклероз, депрессию и тревожность. Установлено, что степень тяжести псориатического процесса, продолжительность заболевания и возраст пациентов являются важными факторами, определяющими частоту развития коморбидностей [1,[6][7][8][9][10][11][12]. При тяжелых формах дерматоза с большой площадью поражения кожи длительный (более 10 лет) псориатический анамнез, а также возраст старше 50 лет являются неблагоприятными факторами для развития коморбидных состояний.…”

unclassified

Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis

Бакулев

2018

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Эволюция представлений о псориазе и терапевтических подходах по ведению пациентов. BCD-085 -первый отечественный генноинженерный биологический препарат для лечения больных псориазом Бакулев А. Л.Саратовский государственный медицинский университет им. В.И. Разумовского Министерства здравоохранения Российской Федерации 410012, Российская Федерация, г. Саратов, ул. Большая Казачья, д. 112 В обзоре обсуждается системный характер псориаза. Понимание специалистами, что данный дерматоз не является исключительно заболеванием кожного покрова, а патогенетически взаимосвязан с развитием ряда коморбидных состояний, не только имеет важное теоретическое значение, но также позволяет обсуждать целесообразность изменения терапевтической стратегии в отношении пациентов со среднетяжелыми и тяжелыми формами дерматоза, сопровождающимися непрерывно-рецидивирующим течением и наличием коморбидных состояний. Долгосрочное применение средств системной терапии, в том числе генно-инженерных биологических препаратов, в таких случаях является теоретически обоснованным и обеспечивает контроль над основными клиническими проявлениями заболевания. Приводятся данные по влиянию отечественного оригинального препарата BCD-085 -ингибитора IL17 -на ключевые звенья иммунопатогенеза псориаза, его эффективность и безопасность у лиц, имеющих среднетяжелые и тяжелые формы данного дерматоза. BCD-085 демонстрирует быстрый и высокий терапевтический ответ по индексам PASI75, PASI90, PASI100 и sPGA в течение первых 12 недель терапии. Согласно данным, имеющимся на данный момент, BCD-085 обладает благоприятным профилем безопасности и отсутствием значимой с клинической точки зрения иммуногенности. Ключевые слова: псориаз, коморбидные состояния, терапия, генно-инженерные биологические препараты, BCD-085, эффективность, безопасность, иммуногенность Конфликт интересов: автор заявляет об отсутствии потенциального конфликта интересов, требующего раскрытия в данной статье. Для цитирования: Бакулев А. Л. Эволюция представлений о псориазе и терапевтических подходах по ведению пациентов. BCD-085 -первый отечественный генно-инженерный биологический препарат для лечения больных псориазом. Вестник дерматологии и венерологии. 2018;94(5):26-32. https://doi.Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis Andrey L. Bakulev Saratov State Medical University named after V.I. Razumovsky, Ministry of Health of the Russian Federation Bolshaya Kazachia str., 112, Saratov, 410012, Russian FederationThis review paper discusses the systemic character of psoriasis. For medical specialists, it is of crucial importance to understand that psoriasis is not exclusively a skin disease; rather, it is pathogenetically connected with the development of a number of comorbid conditions. This fact has a practical significance in terms of choosing therapeutic strategies for managing patients with medium and severe dermato...

show abstract

Association of Metabolic Syndrome in Chronic Plaque Psoriasis Patients and their Correlation with Disease Severity, Duration and Age: A Case Control Study from Western Maharashtra

Cited by 20 publications

References 29 publications

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Association of metabolic syndrome with pediatric psoriasis: a case‐control study in Kabul, Afghanistan

Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis

Contact Info

Product

Resources

About